A comparison of fluorine‐18 fluoro‐deoxyglucose PET and technetium‐99m sestamibi in assessing patients with multiple myeloma

Objective:  The extent of disease in patients with multiple myeloma or related conditions may be difficult to assess. In previous small studies, both FDG‐PET (PET) and Tc‐99m sestamibi scans (MIBI) have identified sites of occult disease in myeloma.

[1]  L. Pace,et al.  99mTc-sestaMIBI Scintigraphy in Thalidomide-treated Refractory or Relapsed Multiple Myeloma Patients , 2003, Leukemia & lymphoma.

[2]  A. Waxman,et al.  Whole-body (18)F-FDG PET identifies high-risk myeloma. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  P. Conti,et al.  Diagnostic utility of FDG PET in multiple myeloma , 2002, Skeletal Radiology.

[4]  N. Malliaraki,et al.  Correlation between the uptake of Tc-99m-sestaMIBI and prognostic factors in patients with multiple myeloma. , 2002, Clinical and laboratory haematology.

[5]  S. Barrington,et al.  Fluoro‐deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma , 2002, British journal of haematology.

[6]  R. A. Saber.  Technetium-99m Sestamibi in Multiple Myeloma , 2002 .

[7]  P. Filardi,et al.  Diagnostic accuracy of low-dose dobutamine echocardiography in predicting post-revascularisation recovery of function in patients with chronic coronary artery disease: relationship to thallium-201 uptake , 2001, European Journal of Nuclear Medicine.

[8]  M. Salvatore,et al.  Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma , 2001, European Journal of Nuclear Medicine.

[9]  M. Svaldi,et al.  Technetium-99m-sestamibi scintigraphy: an alternative approach for diagnosis and follow-up of active myeloma lesions after high-dose chemotherapy and autologous stem cell transplantation , 2001, Annals of Hematology.

[10]  M. Salvatore,et al.  Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow-up , 2001, European Journal of Nuclear Medicine.

[11]  M. Gobbi,et al.  Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: a useful tool for the identification and follow-up of myeloma bone disease. , 2001, Haematologica.

[12]  S. Larson,et al.  Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  R. Kyle,et al.  Smoldering multiple myeloma. , 1980, The New England journal of medicine.